Awell, the leading CareOps platform, is partnering with Astrana Health Inc. (NASDAQ:ASTH) to scale Awell’s platform across Astrana Health’s network, enhancing patient care, provider experience, and operational efficiency.
Awell empowers clinical and operational teams to design, implement, and improve workflows without IT, enabling providers like Astrana Health to orchestrate over 23 million care activities annually, from patient onboarding to chronic disease management.
The collaboration reflects Awell’s commitment to value-based care and aligns with Astrana Health’s mission to empower providers with advanced technology and clinical tools.
Researchers performed a multi-omics evaluation of HSPCs obtained from individuals with myeloproliferative neoplasms transforming to TP53-related secondary forms of acute myeloid leukemia.
Awell’s CareOps Platform Expands with Astrana Health
by Syed Hamza Sohail Leave a Comment
Chronic inflammation’s influence on TP53 mutations in leukemia evolution explored in new study
Researchers performed a multi-omics evaluation of HSPCs obtained from individuals with myeloproliferative neoplasms transforming to TP53-related secondary forms of acute myeloid leukemia.
Beam takes its time to the clinic; Aspen gets clearance to test Parkinson’s cell therapy in humans
Over a year and a half since Beam Therapeutics received clearance from the FDA to test its base-edited sickle cell therapy in humans, it has
Is there an association between muscle-building supplements and DNA damage in resistance training practitioners?
A recent study investigated whether muscle-building supplements are associated with DNA damage in individuals practicing resistance training.